← Leaderboards

Joseph M McCune

University Of California San Francisco

Google Scholar ↗PubMed ↗ORCID ↗

$87,907,605

Attributed

$88,789,931

Total exposure

52

Grants

39

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $44.7M · FY2005–16

$50M$37.5M$25M$12.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

Funding mix

By agency

NIH$160,674,062 · 56

By mechanism

UL1$87,574,253 · 15

U19$33,948,650 · 4

R01$13,500,838 · 6

KL2$7,145,985 · 2

R37$4,995,872 · 1

DP1$4,175,451 · 1

Top collaborators

Most similar at University Of California San Francisco

Same institution · by research overlap

Matthew G Dorsey$21,862,621
Paul A Volberding$41,854,974
Peter W Hunt$24,497,989
Joel D. Ernst$38,250,253
Jacquelyn J. Maher$16,758,504

Others in their field

Top investigators on “Clinical Research”

David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
Sonia M Thomas · Research Triangle Institute$700,865,642
Jeffrey P Krischer · University Of South Florida$611,867,176
Barton F Haynes · Duke University$538,862,577

Research focus

Clinical ResearchHiv InfectionsImmune ResponseCellsResearch StudyT-LymphocyteHuman SubjectInfectionResponseVirusViralDesignImmune SystemImmuneCd4 Positive T LymphocytesFlow CytometryResourcesResearch PersonnelSan FranciscoGrantFosteringFundingIn VivoInflammation

Grant awards (145)

Layering of the human immune system, viral infections, and childhood asthma$367,565

R01 · FY2016 · AI · contact PI

Interferon-independent mechanisms of malaria restriction by helper T cells$68,342

R21 · FY2016 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$5,807,143

U19 · FY2015 · AI

Timing of ART and homeostasis of the persistent HIV reservoir in the adult$765,501

R01 · FY2015 · AI · contact PI

Layering of the human immune system, viral infections, and childhood asthma$463,121

R01 · FY2015 · AI · contact PI

The impact of TB co-infection on the reservoir of persistent HIV in vivo$239,551

R21 · FY2015 · AI · contact PI

Interferon-independent mechanisms of malaria restriction by helper T cells$237,750

R21 · FY2015 · AI · contact PI

Novel flow cytometry-based assay for HIV-infected cells$210,643

R21 · FY2015 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$7,309,244

U19 · FY2014 · AI

Layering of the human immune system, viral infections, and childhood asthma$375,979

R01 · FY2014 · AI · contact PI

The Impact of Tolerance in the Newborn on Lentiviral Infection$373,937

R01 · FY2014 · AI · contact PI

Mechanisms of effective adaptive immunity in HCV treatment$276,507

U19 · FY2014 · AI · contact PI

Novel flow cytometry-based assay for HIV-infected cells$220,601

R21 · FY2014 · AI · contact PI

Administrative Core$65,349

U19 · FY2014 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$5,568,822

U19 · FY2013 · AI

The Impact of Tolerance in the Newborn on Lentiviral Infection$683,272

R01 · FY2013 · AI · contact PI

Bay Area Hepatitis C Cooperative Research Center$671,045

U19 · FY2013 · AI · contact PI

Layering of the human immune system, viral infections, and childhood asthma$383,225

R01 · FY2013 · AI · contact PI

Mechanisms of effective adaptive immunity in HCV treatment$259,066

U19 · FY2013 · AI · contact PI

Administrative Core$76,395

U19 · FY2013 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$6,511,956

U19 · FY2012 · AI

The Impact of Tolerance in the Newborn on Lentiviral Infection$740,981

R01 · FY2012 · AI · contact PI

Bay Area Hepatitis C Cooperative Research Center$717,263

U19 · FY2012 · AI · contact PI

Interruption of maternal-fetal transmission of HIV$715,530

R01 · FY2012 · AI · contact PI

Mechanisms of effective adaptive immunity in HCV treatment$341,423

U19 · FY2012 · AI · contact PI

Layering of the human immune system, viral infections, and childhood asthma$328,080

R01 · FY2012 · AI · contact PI

Human immune system layering and the neonatal response to vaccines$193,125

R21 · FY2012 · AI · contact PI

Administrative Core$101,152

U19 · FY2012 · AI · contact PI

The Impact of Tolerance in the Newborn on Lentiviral Infection$2,798

R01 · FY2012 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$4,301,805

U19 · FY2011 · AI

Interruption of maternal-fetal transmission of HIV$753,476

R01 · FY2011 · AI · contact PI

The Impact of Tolerance in the Newborn on Lentiviral Infection$744,029

R01 · FY2011 · AI · contact PI

Bay Area Hepatitis C Cooperative Research Center$709,063

U19 · FY2011 · AI · contact PI

Human immune system layering and the neonatal response to vaccines$231,750

R21 · FY2011 · AI · contact PI

ROLE OF IMMUNE ACTIVATION IN SIV PATHOGENESIS$191,444

P51 · FY2011 · RR · contact PI

Mechanisms of effective adaptive immunity in HCV treatment$164,762

U19 · FY2011 · AI · contact PI

INTERRUPTION OF MATERNAL-FETAL TRANSMISSION OF HIV$143,611

P51 · FY2011 · RR · contact PI

Administrative Core$100,635

U19 · FY2011 · AI · contact PI

The Impact of Tolerance in the Newborn on Lentiviral Infection$783,538

R01 · FY2010 · AI · contact PI

Bay Area Hepatitis C Cooperative Research Center$745,655

U19 · FY2010 · AI · contact PI

Interruption of maternal-fetal transmission of HIV$622,305

R01 · FY2010 · AI · contact PI

Nonhuman Primate Model for the Evaluation of the Immunodulatory Effects of Morphi$365,652

P01 · FY2010 · DA · contact PI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$340,470

R37 · FY2010 · AI · contact PI

Model for the Evaluation of the Immunomodulatory Effects of Opioid Addiction, Wit$156,378

P01 · FY2010 · DA

ROLE OF IMMUNE ACTIVATION IN SIV PATHOGENESIS$152,094

P51 · FY2010 · RR · contact PI

Mechanisms of effective adaptive immunity in HCV treatment$126,674

U19 · FY2010 · AI · contact PI

INTERRUPTION OF MATERNAL-FETAL TRANSMISSION OF HIV$114,105

P51 · FY2010 · RR · contact PI

Administrative Core$94,691

U19 · FY2010 · AI · contact PI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$548,386

R37 · FY2009 · AI · contact PI

Interruption of maternal-fetal transmission of HIV$545,915

R01 · FY2009 · AI · contact PI

Nonhuman Primate Model for the Evaluation of the Immunodulatory Effects of Morphi$315,567

P01 · FY2009 · DA · contact PI

Model for the Evaluation of the Immunomodulatory Effects of Opioid Addiction, Wit$248,524

P01 · FY2009 · DA

ROLE OF IMMUNE ACTIVATION IN SIV PATHOGENESIS$146,580

P51 · FY2009 · RR · contact PI

CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$9,537,281

UL1 · FY2008 · RR · contact PI

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$4,675,145

UL1 · FY2008 · RR · contact PI

CTSA INFRASTRUCTURE FOR AIDS RESEARCH$3,668,691

UL1 · FY2008 · RR · contact PI

CTSA INFRASTRUCTURE FOR CLINICAL TRIALS AND PEDIATRIC RESEARCH$1,496,118

UL1 · FY2008 · RR · contact PI

NIH Director's Pioneer Award (RMI)$754,346

DP1 · FY2008 · OD · contact PI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$531,854

R37 · FY2008 · AI · contact PI

Nonhuman Primate Model for the Evaluation of the Immunodulatory Effects of Morphi$343,397

P01 · FY2008 · DA · contact PI

ROLE OF REGULATORY T CELLS IN SIV PATHOGENESIS$168,995

P51 · FY2008 · RR · contact PI

Clinical and Translational Science Institute$168,890

UL1 · FY2008 · RR · contact PI

Clinical and Translational Science Institute$167,039

UL1 · FY2008 · RR · contact PI

Model for the Evaluation of the Immunomodulatory Effects of Opioid Addiction, Wit$150,125

P01 · FY2008 · DA

Clinical and Translational Science Institute$100,000

UL1 · FY2008 · RR · contact PI

Clinical and Translational Science Institute$19,007,879

UL1 · FY2007 · RR · contact PI

CTSA INFRASTRUCTURE FOR AIDS RESEARCH$14,579,386

UL1 · FY2007 · RR · contact PI

Clinical and Translational Science Institute$3,386,657

KL2 · FY2007 · RR · contact PI

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$1,948,766

UL1 · FY2007 · RR · contact PI

CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$1,670,356

UL1 · FY2007 · RR · contact PI

NIH Director's Pioneer Award (RMI)$752,109

DP1 · FY2007 · OD · contact PI

CTSA INFRASTRUCTURE FOR PEDIATRIC & CLINICAL TRIALS$556,710

UL1 · FY2007 · RR · contact PI

Thymic Function in Adults With HIV-1 Disease$529,155

U01 · FY2007 · AI · contact PI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$524,704

R37 · FY2007 · AI · contact PI

Assessing Laboratory Correlates of Immune Protection$474,833

R01 · FY2007 · AI · contact PI

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE$333,980

UL1 · FY2007 · RR · contact PI

Clinical and Translational Science Institute$326,236

TL1 · FY2007 · RR · contact PI

Anti-Gag Antibodies and Enhancement of Lentiviral Disease Progression$313,379

R21 · FY2007 · AI · contact PI

ROLE OF REGULATORY T CELLS IN SIV PATHOGENESIS$181,571

P51 · FY2007 · RR · contact PI

Clinical and Translational Science Institute$81,319

UL1 · FY2007 · RR · contact PI

CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: GLOBAL HEALTH PROGRAM$81,319

UL1 · FY2007 · RR · contact PI

Clinical and Translational Science Institute$14,750,687

UL1 · FY2006 · RR · contact PI

CTSA INFRASTRUCTURE FOR AIDS RESEARCH$13,695,222

UL1 · FY2006 · RR · contact PI

CTSA: K12 COMPONENT$1,879,664

KL2 · FY2006 · RR · contact PI

Clinical and Translational Science Institute$1,879,664

KL2 · FY2006 · RR · contact PI

NIH Director's Pioneer Award (RMI)$749,667

DP1 · FY2006 · OD · contact PI

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE$553,475

UL1 · FY2006 · RR · contact PI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$527,464

R37 · FY2006 · AI · contact PI

Thymic Function in Adults With HIV-1 Disease$526,081

U01 · FY2006 · AI · contact PI

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$437,632

UL1 · FY2006 · RR · contact PI

Assessing Laboratory Correlates of Immune Protection$435,470

R01 · FY2006 · AI · contact PI

Assessing Laboratory Correlates of Immune Protection$435,470

R01 · FY2006 · AI · contact PI

Anti-Gag Antibodies and Enhancement of Lentiviral Disease Progression$335,440

R21 · FY2006 · AI · contact PI

Clinical and Translational Science Institute$313,946

TL1 · FY2006 · RR · contact PI

CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$64,358

UL1 · FY2006 · RR · contact PI

NIH Director's Pioneer Award (RMI)$831,337

DP1 · FY2005 · OD

Thymic Function in Adults With HIV-1 Disease$661,501

U01 · FY2005 · AI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$551,380

R37 · FY2005 · AI

Assessing Laboratory Correlates of Immune Protection$451,832

R01 · FY2005 · AI

NIH Director's Pioneer Award (RMI)$129,992

DP1 · FY2005 · OD

USE OF HGH TO ENHANCE THYMOPOIESIS AND FACILITATE IMMUNE RESTORATION IN HIV$93,240

M01 · FY2005 · RR

CORE LABORATORY ASSAY DEVELOPMENT, VALIDATION, AND QUALITY CONTROL PROGRAM$25,773

M01 · FY2005 · RR

EVALUATION OF THYMIC SIZE AND FUNCTION IN HIV DISEASE$757

M01 · FY2005 · RR

NIH Director's Pioneer Award (RMI)$958,000

DP1 · FY2004 · OD

Thymic Function in Adults With HIV-1 Disease$523,849

U01 · FY2004 · AI

Assessing Laboratory Correlates of Immune Protection$438,672

R01 · FY2004 · AI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$398,365

R37 · FY2004 · AI

Use of HGH to enhance thymopoiesis and facilitate immune restoration in HIV$66,280

M01 · FY2004 · RR

STI to promote HIV-1 immunity$43,369

M01 · FY2004 · RR

Evaluation of thymic size and function in HIV disease$3,272

M01 · FY2004 · RR

Thymic Function in Adults With HIV-1 Disease$709,914

U01 · FY2003 · AI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$398,365

R37 · FY2003 · AI

Assessing Laboratory Correlates of Immune Protection$252,449

R01 · FY2003 · AI

THYMIC FUNCTION IN ADULTS WITH HIV1 DISEASE$427,501

R01 · FY2002 · AI

FLOW CYTOMETRY STUDY OF T CELL RESPONSES TO HIV VACCINES$375,184

R01 · FY2002 · AI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$358,529

R37 · FY2002 · AI

Beckman Coulter BioMek 2000 Workstation and Accessories$123,797

S10 · FY2002 · RR

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND LYMPHOID IRRADIATION IN HIV DISEASE$0

M01 · FY2002 · RR

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND LYMPHOID IRRADIATION IN HIV DISEASE$0

M01 · FY2002 · RR

EVALUATION OF THYMIC MASS IN HIV DISEASE$0

M01 · FY2002 · RR

EVALUATION OF THYMIC MASS IN HIV DISEASE$0

M01 · FY2002 · RR

MECHANISMS OF RESISTANCE TO FAS-INDUCED APOPTOSIS IN HUMAN THYMOCYTES$0

P01 · FY2002 · AI

BONE MARROW IN HIV+ INDIVIDUALS$0

M01 · FY2002 · RR

BONE MARROW IN HIV+ INDIVIDUALS$0

M01 · FY2002 · RR

THYMIC FUNCTION IN ADULTS WITH HIV1 DISEASE$415,051

R01 · FY2001 · AI

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$398,365

R37 · FY2001 · AI

FLOW CYTOMETRY STUDY OF T CELL RESPONSES TO HIV VACCINES$364,782

R01 · FY2001 · AI

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND LYMPHOID IRRADIATION IN HIV DISEASE$0

M01 · FY2001 · RR

MECHANISMS OF RESISTANCE TO FAS-INDUCED APOPTOSIS IN HUMAN THYMOCYTES$0

P01 · FY2001 · AI

BONE MARROW IN HIV+ INDIVIDUALS$0

M01 · FY2001 · RR

EVALUATION OF THYMIC MASS IN HIV DISEASE$0

M01 · FY2001 · RR

MOFLO TM HIGH PERFORMANCE FLOW CYTOMETER$499,338

S10 · FY2000 · RR

HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM$417,990

R37 · FY2000 · AI

THYMIC FUNCTION IN ADULTS WITH HIV1 DISEASE$402,965

R01 · FY2000 · AI

FLOW CYTOMETRY STUDY OF T CELL RESPONSES TO HIV VACCINES$377,377

R01 · FY2000 · AI

MECHANISMS OF RESISTANCE TO FAS-INDUCED APOPTOSIS IN HUMAN THYMOCYTES$156,753

P01 · FY2000 · AI

EVALUATION OF THYMIC MASS IN HIV DISEASE$564

M01 · FY2000 · RR

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND LYMPHOID IRRADIATION IN HIV DISEASE$564

M01 · FY2000 · RR

BONE MARROW IN HIV+ INDIVIDUALS$0

M01 · FY2000 · RR

BONE MARROW IN HIV+ INDIVIDUALS$0

M01 · FY2000 · RR

EVALUATION OF THYMIC MASS IN HIV DISEASE$0

M01 · FY2000 · RR

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND LYMPHOID IRRADIATION IN HIV DISEASE$0

M01 · FY2000 · RR

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND LYMPHOID IRRADIATION IN HIV DISEASE$0

M01 · FY2000 · RR

EVALUATION OF THYMIC MASS IN HIV DISEASE$0

M01 · FY2000 · RR

BONE MARROW IN HIV+ INDIVIDUALS$0

M01 · FY2000 · RR